Eli Lilly and Company (NYSE:LLY) Shares Acquired by Kellett Wealth Advisors LLC

Kellett Wealth Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 5.4% in the 4th quarter, HoldingsChannel reports. The firm owned 1,371 shares of the company’s stock after purchasing an additional 70 shares during the period. Eli Lilly and Company makes up about 0.6% of Kellett Wealth Advisors LLC’s holdings, making the stock its 29th largest holding. Kellett Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $799,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Fairfield Bush & CO. acquired a new position in Eli Lilly and Company in the 1st quarter valued at about $107,000. Roundview Capital LLC grew its holdings in Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares during the period. Merit Financial Group LLC purchased a new stake in Eli Lilly and Company in the 1st quarter valued at about $210,000. NewEdge Advisors LLC grew its holdings in Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter valued at about $561,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6 %

Shares of LLY traded down $4.82 during trading on Thursday, reaching $745.95. The company’s stock had a trading volume of 1,701,145 shares, compared to its average volume of 3,067,708. The company has a fifty day moving average of $764.03 and a two-hundred day moving average of $657.67. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The company has a market cap of $708.77 billion, a price-to-earnings ratio of 129.32, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on LLY shares. Truist Financial restated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.